These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 7999817

  • 1. Lack of correlation between nasal cultures positive for Staphylococcus aureus and the development of S. aureus exit-site infections: results unaffected by routine mupirocin treatment of nasal S. aureus carriage.
    Hanslik TM, Newman L, Tessman M, Morrissey AB, Friedlander MA.
    Adv Perit Dial; 1994; 10():158-62. PubMed ID: 7999817
    [Abstract] [Full Text] [Related]

  • 2. Outcome and clinical implications of a surveillance and treatment program for Staphylococcus aureus nasal carriage in peritoneal dialysis patients.
    Crabtree JH, Hadnott LL, Burchette RJ, Siddiqi RA.
    Adv Perit Dial; 2000; 16():271-5. PubMed ID: 11045309
    [Abstract] [Full Text] [Related]

  • 3. Staphylococcus aureus CAPD-related infections are associated with nasal carriage.
    Lye WC, Leong SO, van der Straaten J, Lee EJ.
    Adv Perit Dial; 1994; 10():163-5. PubMed ID: 7999818
    [Abstract] [Full Text] [Related]

  • 4. The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis--first 6 months' experience.
    Cavdar C, Zeybel M, Atay T, Sifil A, Sanlidag C, Gulay Z, Camsari T.
    Adv Perit Dial; 2004; 20():62-6. PubMed ID: 15384797
    [Abstract] [Full Text] [Related]

  • 5. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis.
    Thodis E, Passadakis P, Panagoutsos S, Bacharaki D, Euthimiadou A, Vargemezis V.
    Adv Perit Dial; 2000; 16():257-61. PubMed ID: 11045306
    [Abstract] [Full Text] [Related]

  • 6. Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7 years.
    Lobbedez T, Gardam M, Dedier H, Burdzy D, Chu M, Izatt S, Bargman JM, Jassal SV, Vas S, Brunton J, Oreopoulos DG.
    Nephrol Dial Transplant; 2004 Dec; 19(12):3140-3. PubMed ID: 15466881
    [Abstract] [Full Text] [Related]

  • 7. Decrease in infections with the introduction of mupirocin cream at the peritoneal dialysis catheter exit site.
    Uttley L, Vardhan A, Mahajan S, Smart B, Hutchison A, Gokal R.
    J Nephrol; 2004 Dec; 17(2):242-5. PubMed ID: 15293524
    [Abstract] [Full Text] [Related]

  • 8. Staphylococcus aureus nasal carriage in children receiving long-term peritoneal dialysis.
    Kingwatanakul P, Warady BA.
    Adv Perit Dial; 1997 Dec; 13():281-4. PubMed ID: 9360700
    [Abstract] [Full Text] [Related]

  • 9. Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage.
    Doebbeling BN, Reagan DR, Pfaller MA, Houston AK, Hollis RJ, Wenzel RP.
    Arch Intern Med; 1994 Jul 11; 154(13):1505-8. PubMed ID: 8018006
    [Abstract] [Full Text] [Related]

  • 10. The treatment of Staphylococcus aureus nasal carriage in pediatric peritoneal dialysis patients.
    Blowey DL, Warady BA, McFarland KS.
    Adv Perit Dial; 1994 Jul 11; 10():297-9. PubMed ID: 7999849
    [Abstract] [Full Text] [Related]

  • 11. Nasal carriage of meticillin resistant Staphylococcus aureus: the prevalence, patients at risk and the effect of elimination on outcomes among outclinic haemodialysis patients.
    Lederer SR, Riedelsdorf G, Schiffl H.
    Eur J Med Res; 2007 Jul 26; 12(7):284-8. PubMed ID: 17933699
    [Abstract] [Full Text] [Related]

  • 12. Safety of targeted perioperative mupirocin treatment for preventing infections after cardiac surgery.
    Shrestha NK, Banbury MK, Weber M, Cwynar RE, Lober C, Procop GW, Karafa MT, Gordon SM.
    Ann Thorac Surg; 2006 Jun 26; 81(6):2183-8. PubMed ID: 16731151
    [Abstract] [Full Text] [Related]

  • 13. Elimination of Staphylococcus aureus in hemodialysis patients.
    Bommer J, Vergetis W, Andrassy K, Hingst V, Borneff M, Huber W.
    ASAIO J; 1995 Jun 26; 41(1):127-31. PubMed ID: 7727815
    [Abstract] [Full Text] [Related]

  • 14. [Use of nasal mupirocin for Staphylococcus aureus: effect on nasal carriers and nosocomial infections].
    García AM, Villa MV, Escudero ME, Gómez P, Vélez MM, Múnera MI, Franco G.
    Biomedica; 2003 Jun 26; 23(2):173-9. PubMed ID: 12872556
    [Abstract] [Full Text] [Related]

  • 15. [Epidemiology and prevention of Staphylococcus aureus infections during hemodialysis].
    Boelaert JR, Van Landuyt HW, De Baere YA, Gheyle DW, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ.
    Nephrologie; 1994 Jun 26; 15(2):157-61. PubMed ID: 8047204
    [Abstract] [Full Text] [Related]

  • 16. Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin.
    Pérez-Fontán M, Rosales M, Rodríguez-Carmona A, Moncalián J, Fernández-Rivera C, Cao M, Valdés F.
    Adv Perit Dial; 1992 Jun 26; 8():242-5. PubMed ID: 1361797
    [Abstract] [Full Text] [Related]

  • 17. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates.
    Paterson DL, Rihs JD, Squier C, Gayowski T, Sagnimeni A, Singh N.
    Transplantation; 2003 Jan 27; 75(2):194-8. PubMed ID: 12548122
    [Abstract] [Full Text] [Related]

  • 18. Emergence of resistance in staphylococci after long-term mupirocin application in patients on continuous ambulatory peritoneal dialysis.
    Cavdar C, Atay T, Zeybel M, Celik A, Ozder A, Yildiz S, Gulay Z, Camsari T.
    Adv Perit Dial; 2004 Jan 27; 20():67-70. PubMed ID: 15384798
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Controlling the usage of intranasal mupirocin does impact the rate of Staphylococcus aureus deep sternal wound infections in cardiac surgery patients.
    Nicholson MR, Huesman LA.
    Am J Infect Control; 2006 Feb 27; 34(1):44-8. PubMed ID: 16443093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.